Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Jazz Pharmaceuticals plc
JAZZ
NASDAQ·Healthcare·Biotechnology·Mkt cap $14.9B
$240.24
▲ +1.15%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$105.00 - $243.32
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 116.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Specialized expertise in orphan and rare diseases with limited competition
- Established market leadership in narcolepsy treatment with Xyrem and Xywav
- Diversified pipeline with multiple late-stage candidates reducing portfolio risk
- Strategic partnerships with biotech innovators enhancing R&D capabilities
Bear Case
1 risk
- Low volatility (beta 0.3).
Growth
Stable outlook
Launch and expansion of next-generation products like Xywav and JZP-324
Value
Deep value opportunity - significant discount to sector peers
Momentum
Hot
+27.0% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying JAZZ right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 4, 2026
MAY 5, 2026
Reported EPS of $6.34 vs $4.67 consensus (+35.8% surprise). Revenue of $1.1B vs $978.5M expected (+9.2%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+35.8%
Next: Aug 4, 2026
Revenue trend · last 8Q
—
—
—
-0%
+2%
+7%
+10%
+19%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$1.0B
$1.1B
$1.1B
$897.8M
$1.0B
$1.1B
$1.2B
$1.1B
Margins · last 8Q
Gross
—
Operating
—
Profit
27.4%
Wall Street consensus
10 analysts · 90% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
90%
Hold
10%
Sell
0%
Median Price Target
$242.00
▲ +0.7% vs $240.24
Latest: Bank of America · Jun 10, 2026
7 analysts covering
vs Industry
How JAZZ stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related
Peers & themes
Peers
No peer data available.
Themes
No themes assigned.